JAMES P. KEESE for TEVA PHARMACEUTICALS USA
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Patent Reform Act of 2008 (S. 3600), Patent Reform Act of 2007 (H.R. 1908 & S. 1145) Preserve Access to Affordable Generics Act (H.R. 1432 & S. 316), Protecting Consumer Access to Generic Drugs Act (H.R 1902), To amend the Federal Food, Drug, and Cosmetic Act to establish requirements for certain petitions submitted to the Food and Drug Administration, and for other purposes (S. 25).
Foreign entity interest: Teva Pharmaceuticals, Ltd., as an indirect parent of Teva Pharmaceuticals, USA, has an interest in the issues listed above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES P KEESE | — |
Budget/Appropriations BUD
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act of 2008 (H.R. 3161 & S. 1859), Matters relating to FDA Office of Generic Drugs funding., President Bush FY 2008 Budget Request - $15.7 million dollars Generic Drug User Fees.
Foreign entity interest: Teva Pharmaceuticals, Ltd., as an indirect parent of Teva Pharmaceuticals, USA, has an interest in the issues listed above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES P KEESE | — |
Pharmacy PHA
Access to Life-Saving Medicine Act (H.R. 1038 & S. 623), Affordable Biologics for Consumers Act (S. 1505), Biologics Price Competition and Innovation Act of 2007 (S. 1695), Consumer Food Safety Act of 2008 (H.R. 3624), Fair Prescription Drug Competition Act (H.R. 806 & S. 438), Food and Drug Import Safety Act of 2007 (H.R. 3610, The Pathway for Biologics Act (H.R. 5629), The Patient Protection and Innovative Biologic Medicines Act (H.R. 1956).
Foreign entity interest: Teva Pharmaceuticals, Ltd., as an indirect parent of Teva Pharmaceuticals, USA, has an interest in the issues listed above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES P KEESE | — |
Trade (domestic/foreign) TRD
Matters relating to Israeli data exclusivity, Matters relating to pharmaceutical provisions in free trade agreements.
Foreign entity interest: Teva Pharmaceuticals, Ltd., as an indirect parent of Teva Pharmaceuticals, USA, has an interest in the issues listed above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES P KEESE | — |
Health Issues HCR
Physician Payments Sunshine Act (S. 2029), Proposal relating to prescription drug anti-counterfeiting efforts. Safeguarding America's Pharmaceuticals Act of 2008 (H.R. 5839).
Foreign entity interest: Teva Pharmaceuticals, Ltd., as an indirect parent of Teva Pharmaceuticals, USA, has an interest in the issues listed above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES P KEESE | — |
Medicare/Medicaid MMM
Saving Our Community Pharmacies Act of 2007 (H.R. 3140), The Fair Medicaid Drug Payment Act of 2007 (H.R. 3700 & S. 1951)
Foreign entity interest: Teva Pharmaceuticals, Ltd., as an indirect parent of Teva Pharmaceuticals, USA, has an interest in the issues listed above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES P KEESE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.